[High-dose chemotherapy in the salvage treatment of metastatic germ cell tumours]

Castillo Muñoz MA
Record ID 32013000376
Spanish
Authors' objectives: Evaluate the efficacy and safety of HDCT treatment comapared to CDCT treatment in gonadal mGCTs (testicular and ovarian tumours) and extragonadal mGCTs (primary site in mediastinum or retroperitoneum), in patients with refractary or relapsing disease after first or second line treatment.
Authors' recommendations: The administration of a single cycle of high-dose chemotherapy follow by haematopoietic stem cell transplant, in second line treat-ment or first salvage treatment in patients with metastatic germ cell tumours (located in testis, retroperitoneum or mediastin-ium) does not improve clinical benefit in terms of overall sur-vival, event-free survival, or response rate in comparison to conventional-dose salvage chemotherapy. Evidence regarding the efficacy of HDCT in patients with mGCTs in first and subsequent salvage treatment has poor quality. Therefore, it cannot be concluded with certainty that the treatment with high-dose chemotherapy improves OS, PFS or RR in this population. There are no studies with an appropriate design evaluating high-dose chemotherapy for relapsed or refractory disease in first or subsequent salvage treatment in patients with ovarian mGCTs. There are no randomized controlled trials which compare high-dose chemotherapy with conventional-dose chemotherapy in second or subsequent salvage treatment in patients with mGCTs. There is a strong need for studies with an appropriate design that considered prognosis factors in patients with mGCTs who relapse or progress after first-line chemotherapy.
Details
Project Status: Completed
Year Published: 2012
URL for published report: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2011_7_TGerminales_NIPO.pdf
URL for additional information: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2011_7_TGerminales_NIPO_eng.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Neoplasms, Germ Cell and Embryonal
  • Salvage Therapy
Contact
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.